adverum.com (ADVM) Year-over-year earnings per share growth for the last twelve months

Will patents and strict FDA control protect Adverum Biotechnologies (ADVM) from competitors? Adverum Biotechnologies is developing the unique Ixo-vec vector, which replaces frequent injections for macular dystrophy with a single procedure. However, cash flows remain unstable and dependent on grants. The quarter-over-quarter EPS trend confirms this volatility, with the current level standing at -55.70.
Financial and market metric breakdowns for adverum.com (ADVM)

Adverum Biotechnologies (ADVM) vulnerability to supply chain disruptions and patent disputes amid geopolitical pressure makes monitoring financial stability critical. The earnings per share dynamics, reflected through the growth rate of quarterly EPS, measures the rate of change in net income adjusted for probability distribution, allowing investors to identify hidden growth potential or the risk of a price collapse during periods of low volatility.